COVID-19, influenza, and respiratory syncytial virus vaccination coverage is low among adults so far this respiratory virus season (2024 to 2025).

Seasonal maternal respiratory syncytial virus vaccination and nirsevimab for infants demonstrate cost-effectiveness.

Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness,” published in the November 2024 issue ...

So far very few Americans have been rolling up their sleeves to get vaccinated against COVID, flu or RSV. Rob Stein is a correspondent and senior editor on NPR's science desk.

Experts worry that the unenthusiastic embrace of vaccines could spark outbreaks and increased hospitalizations.